Document is current
Any future updates will be listed below
-
Authors
Roumiguie, Mathieu https://orcid.org/0000-0002-2412-146X
Contreras-Sanz, Alberto
Kumar, Gunjan
Black, Peter C. https://orcid.org/0000-0002-2919-7068
- License Information
-
More Information
Article History
Received: 16 January 2021
Accepted: 8 July 2021
First Online: 10 August 2021
Competing interests
: M.R. has consulted for Astellas Pharma, AstraZeneca, Pfizer, Janssen Oncology, Bayer, Ferring, Pierre Fabre. P.C.B. has consulted for AbbVie, Astellas Pharma, EMD-Serono, Pfizer, Janssen Oncology, Bayer, Merck, Sanofi Canada, Biosyent, Ferring, Roche Canada, MDxHealth, AstraZeneca, Urogen Pharma, Bristol-Myers Squibb and has received research funding from iProgen. P.C.B. shares a patent (1) Cancer biomarkers and classifiers and uses thereof number 2014344766, 2,928,901, 14856820.7, PCT/CA2014/000787, 15/032,159, (2) Systems methods and compositions for predicting metastasis in bladder cancer number PCT/CA2017/050656, and (3) Molecular subtyping, prognosis ad treatment of bladder cancer number 62/448,921 with Decipher Biosciences. A.C.S. and G.K. declare no competing interests.
